Search clinical trials for: Dyslipaemia

Total 2 results

AstraZeneca

Completed

Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain (DARIOS)

Dyslipaemia | Atherosclerosis Risk | Increased hsCRP | Inflammatory and Oxidative Status in the Spanish Population

Spain
AstraZeneca

Completed

Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

Metabolic Syndrome | Dyslipidemia

Australia

3

Subscribe